ArticleNature communications2026
A pre-train and fine-tune framework for adaptive boosting of pre-trained polygenic risk scores.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polygenic risk scores are widely used for predicting genetic risk across complex diseases and traits, and several pre-trained models have been developed. Few approaches leverage these pre-trained polygenic risk scores to further refine predictive performance. Here, we present Adaptive Boosting of pre-trained Polygenic Risk Socres, a fine-tuning framework that refines pre-trained polygenic risk score models through adaptive variable selection and model boosting to identify additional predictive signals that may not be fully captured by the original models. Simulations show that our framework can identify signals orthogonal to pre-trained polygenic risk scores while controlling false discovery rates. Using UK Biobank data, we fine-tune pre-trained polygenic risk scores for binary diseases and continuous traits, and validate the results across three independent datasets: All of Us, eMERGE, and Penn Medicine Biobank. Real data analyses show that Adaptive Boosting of pre-trained Polygenic Risk Scores achieves statistically significant improvements in several scenarios while maintaining competitive performance in others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.